Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 2/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.51 |
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | PPARG | P37231 | 1/20 | 0.51 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.51 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.51 |
| ▸ | PKLR | P30613 | 1/20 | 0.47 |
| ▸ | GALNT2 | Q10471 | 1/20 | 0.47 |
| ▸ | GALNT1 | Q10472 | 1/20 | 0.47 |
| ▸ | GALNT3 | Q14435 | 1/20 | 0.47 |
| ▸ | GALNT10 | Q86SR1 | 1/20 | 0.47 |
| ▸ | GALNT13 | Q8IUC8 | 1/20 | 0.47 |
| ▸ | GALNT6 | Q8NCL4 | 1/20 | 0.47 |
| ▸ | GALNT14 | Q96FL9 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7987277 | 0.82 | ESR2 (0.70) | ESR2NPSR1RXFP1PKLRGALNT2 | |
| SCHEMBL30629209 | 0.79 | ESR2 (0.66) | ESR2NPSR1RXFP1LMNAPPARG | |
| SCHEMBL26766942 | 0.79 | ESR2 (0.66) | ESR2NPSR1RXFP1LMNAPPARG | |
| SCHEMBL9747411 | 0.76 | MAOA (0.65) | ESR2NPSR1LMNAMAPTCYP2C9 | |
| SCHEMBL30880452 | 0.74 | ESR2 (0.57) | ESR2NPSR1RXFP1LMNAMAPT | |
| SCHEMBL26779869 | 0.74 | ESR2 (0.64) | ESR2NPSR1RXFP1LMNAPPARG | |
| SCHEMBL26779756 | 0.73 | L3MBTL1 (0.57) | NPSR1RXFP1LMNAPPARGNCOA2 | |
| SCHEMBL6825266 | 0.72 | ESR2 (1.00) | ESR2ALDH1A1SMN1; SMN2HSD17B10MAOA | |
| SCHEMBL29853705 | 0.72 | ESR2 (0.66) | ESR2NPSR1RXFP1LMNAPPARG | |
| SCHEMBL26766945 | 0.72 | ESR2 (0.66) | ESR2NPSR1RXFP1LMNAPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024025953-A2 | THERAPEUTIC USES OF UROLITHIN DERIVATIVES | VANDRIA SA (CH) | 2024-02-01 | — | — | WO | disclosed |
| US-11820751-B2 | Urolithin derivatives and methods of use thereof | VANDRIA SA (CH) | 2023-11-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11820751-B2 | Urolithin derivatives and methods of use thereof | NLN, UQCRC2, TUFM | ESR2 4060/4885NPSR1 3213/4885RXFP1 3981/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.